- CITATIONS: 2
|Application ||WB, E|
|Calculated MW||32523 Da|
|Antigen Region||251-281 aa|
|Other Names||Ketohexokinase, Hepatic fructokinase, KHK|
|Target/Specificity||This Ketohexokinase (KHK) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 251-281 amino acids from the C-terminal region of human Ketohexokinase (KHK).|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.|
|Precautions||Ketohexokinase (KHK) Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Catalyzes the phosphorylation of the ketose sugar fructose to fructose-1-phosphate.|
|Tissue Location||Most abundant in liver, kidney, gut, spleen and pancreas. Low levels also found in adrenal, muscle, brain and eye.|
Provided below are standard protocols that you may find useful for product applications.
Ketohexokinase (KHK), or fructokinase, catalyzes conversion of fructose to fructose-1-phosphate. Splice variant 1 is the highly active form found in liver, renal cortex, and small intestine, while splice variant 2 is the lower activity form found in most other tissues. KHK, like glucokinase (GCK) and glucokinase regulator (GCKR), is present in both liver and pancreatic islets. The inhibition of GCK by GCKR is blocked by binding of fructose-1-phosphate to GCKR. The chromosomal proximity of the metabolically connected GCKR and KHK genes has a genetic linkage in type 2 diabetes. Fructosuria, or hepatic fructokinase deficiency, is a benign, asymptomatic defect of intermediary metabolism associated with heterozygosity for G50R and A43T mutations in KHK.
If you have any additional inquiries please email technical services at email@example.com.